Voyager Therapeutics (NASDAQ:VYGR) Cut to Hold at StockNews.com

StockNews.com cut shares of Voyager Therapeutics (NASDAQ:VYGR) from a buy rating to a hold rating in a report published on Friday morning.

A number of other equities analysts also recently weighed in on VYGR. Wedbush started coverage on Voyager Therapeutics in a research report on Friday, November 29th. They set an “outperform” rating and a $11.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a report on Thursday, November 14th. Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. Citigroup initiated coverage on shares of Voyager Therapeutics in a research report on Monday, December 2nd. They set a “buy” rating and a $12.00 price objective for the company. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $14.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $17.00.

Voyager Therapeutics Trading Up 0.3 %

NASDAQ:VYGR opened at $6.27 on Friday. The stock has a market capitalization of $342.53 million, a PE ratio of 8.83 and a beta of 0.90. Voyager Therapeutics has a 1-year low of $5.19 and a 1-year high of $11.72. The firm has a fifty day simple moving average of $6.59 and a 200 day simple moving average of $7.16.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. The firm had revenue of $24.63 million during the quarter, compared to analysts’ expectations of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same quarter last year, the company posted ($0.59) earnings per share. On average, equities analysts predict that Voyager Therapeutics will post -0.89 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total transaction of $34,914.18. Following the sale, the insider now directly owns 86,001 shares of the company’s stock, valued at approximately $500,525.82. This represents a 6.52 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.53% of the stock is owned by insiders.

Institutional Investors Weigh In On Voyager Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Barclays PLC lifted its stake in Voyager Therapeutics by 55.8% during the third quarter. Barclays PLC now owns 104,462 shares of the company’s stock worth $612,000 after purchasing an additional 37,398 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Voyager Therapeutics by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock worth $6,316,000 after buying an additional 6,740 shares in the last quarter. Erste Asset Management GmbH bought a new stake in shares of Voyager Therapeutics during the 3rd quarter worth $6,192,000. Verition Fund Management LLC acquired a new stake in Voyager Therapeutics in the third quarter valued at about $216,000. Finally, BNP Paribas Financial Markets grew its position in Voyager Therapeutics by 30.5% in the third quarter. BNP Paribas Financial Markets now owns 49,235 shares of the company’s stock valued at $288,000 after acquiring an additional 11,516 shares during the last quarter. Institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.